search
Back to results

Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus (EDITION JP II)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Insulin glargine new formulation (HOE901)
Insulin glargine (HOE901)
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria :

o Patients with type 2 diabetes mellitus diagnosed for at least 1 year at the time of screening visit treated with basal insulin in combination with oral antihyperglycemic drugs (OADs) for at least 6 months before screening visit;

Exclusion criteria:

  • Age < 18 years at screening visit;
  • BMI(body mass index) ≥ 35 kg/m2 at screening visit;
  • HbA1c < 7.0% or > 10% (national glycohemoglobin standardization program [NGSP] value) at screening visit;
  • Diabetes other than type 2 diabetes mellitus;
  • Patients on self-monitoring of blood glucose less than 6 months before screening visit;
  • Patients using pre-mix insulins, insulin detemir at 2 times or more a day, or GLP 1 receptor agonists in the last 3 months before screening visit;
  • Patients using mealtime insulin (rapid-acting insulin analogue and short-acting insulin) for more than 10 days in the last 3 months before screening visit;
  • Use of insulin pump in the last 6 months before screening visit;
  • Initiation of new glucose-lowering medications and/or weight loss drugs in the last 3 months before screening visit;
  • Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit;
  • Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number 392226
  • Investigational Site Number 392218
  • Investigational Site Number 392212
  • Investigational Site Number 392209
  • Investigational Site Number 392210
  • Investigational Site Number 392208
  • Investigational Site Number 392217
  • Investigational Site Number 392216
  • Investigational Site Number 392222
  • Investigational Site Number 392223
  • Investigational Site Number 392215
  • Investigational Site Number 392225
  • Investigational Site Number 392205
  • Investigational Site Number 392204
  • Investigational Site Number 392206
  • Investigational Site Number 392201
  • Investigational Site Number 392228
  • Investigational Site Number 392229
  • Investigational Site Number 392230
  • Investigational Site Number 392211
  • Investigational Site Number 392220
  • Investigational Site Number 392227
  • Investigational Site Number 392203
  • Investigational Site Number 392231
  • Investigational Site Number 392224
  • Investigational Site Number 392207
  • Investigational Site Number 392219
  • Investigational Site Number 392221
  • Investigational Site Number 392202
  • Investigational Site Number 392213
  • Investigational Site Number 392214

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

New formulation of insulin glargine

Lantus (insulin glargine)

Arm Description

once daily in the evening on-top of oral antihyperglycemic drug (OADs)

once daily in the evening on-top of OADs

Outcomes

Primary Outcome Measures

Change from baseline in HbA1c

Secondary Outcome Measures

Percentage of HbA1c responders (HbA1c < 7%; < 6.5%)
Change from baseline in FPG
Change from baseline in pre-basal insulin injection SMPG
Change from baseline in 8-point SMPG profiles
Change from baseline in 24-hour mean plasma glucose of SMPG profiles (mean of 8-point values)
Change from baseline in variability of plasma glucose profile
Change from baseline in daily basal insulin dose
Number of patients with various types of hypoglycemia events

Full Information

First Posted
September 14, 2012
Last Updated
June 4, 2014
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT01689142
Brief Title
Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus
Acronym
EDITION JP II
Official Title
A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
September 2012 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at month 6 [week 26]) in japanese patients with type 2 diabetes mellitus. Secondary Objectives: To compare a new formulation of insulin glargine and Lantus in terms of change in fasting plasma glucose (FPG), preinjection plasma glucose, 8-point self-measured plasma glucose (SMPG) profile. To compare a new formulation of insulin glargine and Lantus in terms of occurrence of hypoglycemia
Detailed Description
The duration of study will consist of: Up to 2-week screening period; 6-month open-label comparative efficacy and safety treatment period; 6-month open-label comparative safety extension period; 4-week post-treatment safety follow-up period

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
240 (Actual)

8. Arms, Groups, and Interventions

Arm Title
New formulation of insulin glargine
Arm Type
Experimental
Arm Description
once daily in the evening on-top of oral antihyperglycemic drug (OADs)
Arm Title
Lantus (insulin glargine)
Arm Type
Active Comparator
Arm Description
once daily in the evening on-top of OADs
Intervention Type
Drug
Intervention Name(s)
Insulin glargine new formulation (HOE901)
Intervention Description
Pharmaceutical form: solution Route of administration: subcutaneous
Intervention Type
Drug
Intervention Name(s)
Insulin glargine (HOE901)
Other Intervention Name(s)
Lantus
Intervention Description
Pharmaceutical form: solution Route of administration: subcutaneous
Primary Outcome Measure Information:
Title
Change from baseline in HbA1c
Time Frame
baseline, 6 months
Secondary Outcome Measure Information:
Title
Percentage of HbA1c responders (HbA1c < 7%; < 6.5%)
Time Frame
up to 6 months
Title
Change from baseline in FPG
Time Frame
baseline, 6 months
Title
Change from baseline in pre-basal insulin injection SMPG
Time Frame
baseline, 6 months
Title
Change from baseline in 8-point SMPG profiles
Time Frame
baseline, 6 months
Title
Change from baseline in 24-hour mean plasma glucose of SMPG profiles (mean of 8-point values)
Time Frame
baseline, 6 months
Title
Change from baseline in variability of plasma glucose profile
Time Frame
baseline, 6 months
Title
Change from baseline in daily basal insulin dose
Time Frame
baseline, 6 months
Title
Number of patients with various types of hypoglycemia events
Time Frame
up to 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria : o Patients with type 2 diabetes mellitus diagnosed for at least 1 year at the time of screening visit treated with basal insulin in combination with oral antihyperglycemic drugs (OADs) for at least 6 months before screening visit; Exclusion criteria: Age < 18 years at screening visit; BMI(body mass index) ≥ 35 kg/m2 at screening visit; HbA1c < 7.0% or > 10% (national glycohemoglobin standardization program [NGSP] value) at screening visit; Diabetes other than type 2 diabetes mellitus; Patients on self-monitoring of blood glucose less than 6 months before screening visit; Patients using pre-mix insulins, insulin detemir at 2 times or more a day, or GLP 1 receptor agonists in the last 3 months before screening visit; Patients using mealtime insulin (rapid-acting insulin analogue and short-acting insulin) for more than 10 days in the last 3 months before screening visit; Use of insulin pump in the last 6 months before screening visit; Initiation of new glucose-lowering medications and/or weight loss drugs in the last 3 months before screening visit; Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit; Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number 392226
City
Amagasaki-Shi
Country
Japan
Facility Name
Investigational Site Number 392218
City
Chigasaki-Shi
Country
Japan
Facility Name
Investigational Site Number 392212
City
Chiyoda-Ku
Country
Japan
Facility Name
Investigational Site Number 392209
City
Chuo-Ku
Country
Japan
Facility Name
Investigational Site Number 392210
City
Chuo-Ku
Country
Japan
Facility Name
Investigational Site Number 392208
City
Chuoh-Ku
Country
Japan
Facility Name
Investigational Site Number 392217
City
Ebina-Shi
Country
Japan
Facility Name
Investigational Site Number 392216
City
Fujisawa-Shi
Country
Japan
Facility Name
Investigational Site Number 392222
City
Higashiosaka-Shi
Country
Japan
Facility Name
Investigational Site Number 392223
City
Izumisano-Shi
Country
Japan
Facility Name
Investigational Site Number 392215
City
Kamakura-Shi
Country
Japan
Facility Name
Investigational Site Number 392225
City
Kashiwara-Shi
Country
Japan
Facility Name
Investigational Site Number 392205
City
Kawagoe-Shi
Country
Japan
Facility Name
Investigational Site Number 392204
City
Kawaguchi-Shi
Country
Japan
Facility Name
Investigational Site Number 392206
City
Kisarazu-Shi
Country
Japan
Facility Name
Investigational Site Number 392201
City
Koriyama-Shi
Country
Japan
Facility Name
Investigational Site Number 392228
City
Kurashiki-Shi
Country
Japan
Facility Name
Investigational Site Number 392229
City
Matsuyama-Shi
Country
Japan
Facility Name
Investigational Site Number 392230
City
Matsuyama-Shi
Country
Japan
Facility Name
Investigational Site Number 392211
City
Mitaka-Shi
Country
Japan
Facility Name
Investigational Site Number 392220
City
Nagoya-Shi
Country
Japan
Facility Name
Investigational Site Number 392227
City
Nishinomiya-Shi
Country
Japan
Facility Name
Investigational Site Number 392203
City
Ogawa-Machi, Hikigun
Country
Japan
Facility Name
Investigational Site Number 392231
City
Okawa-Shi
Country
Japan
Facility Name
Investigational Site Number 392224
City
Osaka-Shi
Country
Japan
Facility Name
Investigational Site Number 392207
City
Shinjuku-Ku
Country
Japan
Facility Name
Investigational Site Number 392219
City
Shizuoka-Shi
Country
Japan
Facility Name
Investigational Site Number 392221
City
Takatsuki-Shi
Country
Japan
Facility Name
Investigational Site Number 392202
City
Ushiku-Shi
Country
Japan
Facility Name
Investigational Site Number 392213
City
Yokohama-Shi
Country
Japan
Facility Name
Investigational Site Number 392214
City
Yokohama-Shi
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
30160030
Citation
Bolli GB, Wysham C, Fisher M, Chevalier S, Cali AMG, Leroy B, Riddle MC. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. Diabetes Obes Metab. 2019 Feb;21(2):402-407. doi: 10.1111/dom.13515. Epub 2018 Oct 2.
Results Reference
derived
PubMed Identifier
26662838
Citation
Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016 Apr;18(4):366-74. doi: 10.1111/dom.12618. Epub 2016 Jan 21.
Results Reference
derived

Learn more about this trial

Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs